NEWS

What we are up to:

SSI Diagnostica continues strong growth journey by merging with Virginia-based TECHLAB

SSI Diagnostica Group (SSID), a global in-vitro diagnostics company backed by Adelis Equity Partners, has experienced significant growth in recent years based on its ability for new product innovation, expansion into international markets and strategic acquisitions. SSID’s latest transformational acquisition is the Virginia-based firm TechLab, Inc., a leading developer and manufacturer of rapid infectious disease … Continue reading

October 14, 2022

Characterization of Clostridioides difficile Strains from an Outbreak Using MALDI-TOF Mass Spectrometry

A recent study in Microorganisms reports the first case of a C. difficile tcdA+/tcdB outbreak strain. This C. difficile strain has a functional copy of the Toxin A gene (tcdA) that produces Toxin A but contains a mutation in the Toxin B gene (tcdB), limiting the ability to detect infections by molecular tests that target the tcdB region to detect infection. Click here to view the article. … Continue reading

August 11, 2022

The Microbiome and Recurrent Clostridioides difficile

Listen to The Microbiome and Recurrent Clostridioides difficile: Trust Your Gut (medscape.org), a CME accredited webinar led by Dr. Feuerstadt, Dr. Oneto, and Dr. Khanna, which discusses the burden of recurrent C. difficile infections (CDI) on patients & healthcare facilities. Patients with inflammatory bowel disease (IBD) who may be experiencing a flare should be tested for C. diff. A toxin-based … Continue reading

June 10, 2022

Testing for Clostridioides difficile and its disease

C. difficile causes 5-15% of hospital-acquired diarrheas and a growing number of community acquired diarrheas.  The infection can also be asymptomatic with carriage occurring frequently.  Each testing method has its strengths and weaknesses, but a multistep algorithm combines the sensitivity of a screen with the specificity of a toxin test to optimize patient care, minimize overdiagnosis,Continue reading

January 3, 2022